Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 4,160 shares of common stock. The shares were sold on May 21, 2026 at an average price of $53.257 per share to cover tax withholding obligations from vesting Restricted Stock Units.
According to the disclosure, this was a required "sell to cover" transaction under the company’s equity incentive plans and did not represent a discretionary trade by Finn. After the sale, he directly held 274,804 shares of Twist Bioscience common stock.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 1,642 shares of Common Stock at $53.257 per share. According to the filing, these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, pursuant to a mandated “sell to cover” election rather than a discretionary trade. After this transaction, Cho directly holds 134,299 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported an insider stock sale tied to tax withholding. On May 21, 2026, he sold 688 shares of common stock at $53.257 per share in an open-market transaction.
According to the footnote, the shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans, and did not represent discretionary trading. After this mandated “sell to cover” transaction, Werner directly holds 48,986 common shares of Twist Bioscience.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a mandated sale of 6,888 shares of Common Stock on May 21, 2026 at an average price of $53.257 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, and the transaction did not represent a discretionary trade by the CEO. Following this transaction, Leproust directly held 846,872 shares of Twist Bioscience Common Stock and retained employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share, expiring on August 31, 2030.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,019 shares of common stock at an average price of $53.257 per share. According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans and were not discretionary trades. After this transaction, Laponis directly holds 116,675 shares of Twist Bioscience common stock.
TWST submitted a Form 144 notice reporting the proposed sale of 800 shares of Common Stock arising from restricted stock vesting on 05/22/2026. The filing lists several prior dispositions in 2026 by Robert F. Werner, including sales of 1,693, 246, 164, 4,961, and 688 shares on various dates with dollar proceeds shown. The filing names Fidelity Brokerage Services LLC as the broker and classifies the 800 shares as compensation-related shares.
TWST affiliate submitted a Form 144 notice that lists 500 shares of Common Stock proposed for sale. The filing shows these shares relate to a Restricted Stock Vesting event dated 02/07/2024. The filing also records prior sales by Melissa Starovasnik of 1,000 shares on 04/01/2026 for $51,000 and 500 shares on 04/27/2026 for $30,915.
TWST: Rule 144 notice of proposed sales and recent dispositions. The filing lists 1,399 shares identified under a restricted stock vesting entry dated 05/20/2026 and records multiple sales by Paula Green during February–May 2026 (1,465; 935; 297; 1,116 shares) with dollar proceeds shown alongside each trade. The submission describes the securities as Common shares and the broker on record as Fidelity Brokerage Services LLC.
Adam Laponis submitted a Form 144 notice reporting proposed sales of Common shares of TWST. The filing lists multiple sales in the past three months: 2,085 shares ($97,389.93), 2,597 shares ($129,561.48), 3,000 shares ($165,000.00), and 4,000 shares ($240,000.00). The filing also notes a restricted stock vesting event dated 05/20/2026.
Twist Bioscience Corp filed a Form 144 notice to sell 6,888 shares of Common Stock related to restricted stock vesting on 05/20/2026. The filing also lists multiple secondary transactions by Emily M. Leproust within the prior three months, including sales of 7,205 shares on 02/23/2026 and 8,061 shares on 04/22/2026.
The filing is a routine insider notice of proposed resale under securities rules and records recent dispositions by a reporting person; it does not state proceeds recipients beyond the selling person or additional conditions.